enGene Holdings Inc. Warrants
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGen… Read more
enGene Holdings Inc. Warrants - Asset Resilience Ratio
enGene Holdings Inc. Warrants (ENGNW) has an Asset Resilience Ratio of 64.87% as of October 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how enGene Holdings Inc. Warrants's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down enGene Holdings Inc. Warrants's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $143.66 Million | 64.87% |
| Total Liquid Assets | $143.66 Million | 64.87% |
Asset Resilience Insights
- Very High Liquidity: enGene Holdings Inc. Warrants maintains exceptional liquid asset reserves at 64.87% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
enGene Holdings Inc. Warrants Industry Peers by Asset Resilience Ratio
Compare enGene Holdings Inc. Warrants's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for enGene Holdings Inc. Warrants (2023–2025)
The table below shows the annual Asset Resilience Ratio data for enGene Holdings Inc. Warrants.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-10-31 | 64.87% | $143.66 Million | $221.47 Million | +43.85pp |
| 2024-10-31 | 21.02% | $65.40 Million | $311.17 Million | +20.93pp |
| 2023-10-31 | 0.09% | $76.00K | $86.96 Million | -- |